AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38416468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 88
Study 38416468 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 88
Study 38416468 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 88
Study 38416468 — intervention group
Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 88
Study 38416468 — intervention group
Group type: COMPARATOR
Intervention: Waiting group after receiving 1-Hz rTMS
Number of subjects: 88
Study 38416472 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-first strategy
Number of subjects: 3561
Study 38416472 — intervention group
Group type: COMPARATOR
Intervention: Direct-to-ICA strategy
Number of subjects: 3561
Study 38416500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (34.0-35.0 °C)
Number of subjects: 509
Study 38416500 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.5-37.5 °C)
Number of subjects: 509
Study 38416544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype sensor for swallowing monitoring
Number of subjects: 166
Study 38416559 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and retention strategies using social media (Instagram)
Number of subjects: 1216
Study 38416559 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative communication methods (Instagram)
Number of subjects: 1216
Study 38416559 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct messaging on Instagram
Number of subjects: 1216
Study 38416559 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic data collection
Number of subjects: 1216
Study 38416559 — intervention group
Group type: EXPERIMENTAL
Intervention: Other alternative means of contact (Facebook, alternative email)
Number of subjects: 1216
Study 38416574 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital weight gain prevention intervention (Balance)
Number of subjects: 443
Study 38416574 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 443
Study 38416809 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metformin (1000 mg/d) with TCA peeling
Number of subjects: 60
Study 38416809 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metformin (500 mg/d) with TCA peeling
Number of subjects: 60
Study 38416809 — intervention group
Group type: COMPARATOR
Intervention: Placebo with TCA peeling
Number of subjects: 60
Study 38416811 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight-Line (SL) closure
Number of subjects: 50
Study 38416811 — intervention group
Group type: COMPARATOR
Intervention: W-plasty closure
Number of subjects: 50
Study 38416865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil with Aripiprazole Lauroxil NanoCrystal Dispersion
Number of subjects: 0
Study 38416865 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone Palmitate Monthly
Number of subjects: 0
Study 38417017 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery System with Automatic Meal Bolus
Number of subjects: 0
Study 38417039 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0
Study 38417039 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-alcohol consumers)
Number of subjects: 0
Study 38417060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV induction therapy
Number of subjects: 994
Study 38417209 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 50
Study 38417209 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive index model (PIV)
Number of subjects: 50
Study 38417209 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 50
Study 38417207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Intervention Package (CBIP)
Number of subjects: 77
Study 38417207 — intervention group
Group type: COMPARATOR
Intervention: Routine PVC procedure (Control)
Number of subjects: 77
Study 38417221 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1-h high sensitivity troponin T (hs-cTnT) algorithm
Number of subjects: 1430
Study 38417277 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265) 1050 mg BID (FBS capsule) or 750 mg BID (SDD tablet)
Number of subjects: 68
Study 38417277 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265)
Number of subjects: 68
Study 38417277 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265) with tumor testing
Number of subjects: 68
Study 38417277 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib (MGCD265) with ctDNA testing
Number of subjects: 68
Study 38417400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Self-Management Program
Number of subjects: 94
Study 38417400 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 94
Study 38417440 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose camrelizumab alone (n = 20)
Number of subjects: 60
Study 38417440 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation alone (n = 20)
Number of subjects: 60
Study 38417440 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab + Microwave ablation (n = 20)
Number of subjects: 60
Study 38417440 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 38417549 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMs) (15 micronutrients including IFA)
Number of subjects: 1599
Study 38417549 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Number of subjects: 1599
Study 38417549 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) only
Number of subjects: 1599
Study 38417552 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic hygroscopic dilators
Number of subjects: 174
Study 38417552 — intervention group
Group type: COMPARATOR
Intervention: 30-mL silicone single-balloon catheter
Number of subjects: 174
Study 38417773 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-nasal cooling within 20 minutes from EMS arrival followed by in-hospital hypothermia at 33°C for 24 hours
Number of subjects: 1022
Study 38417773 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with no prehospital or in-hospital cooling
Number of subjects: 1022
Study 38417773 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-nasal cooling
Number of subjects: 1022
Study 38417773 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1022
Study 38417976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus rilpivirine (50 mg dolutegravir plus 25 mg rilpivirine once daily)
Number of subjects: 140
Study 38417976 — intervention group
Group type: COMPARATOR
Intervention: Control group (current antiretroviral therapy regimen)
Number of subjects: 140
Study 38418002 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing at 1 year
Number of subjects: 1192
Study 38418002 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1192
Study 38418004 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 5661
Study 38418004 — intervention group
Group type: COMPARATOR
Intervention: ramipril
Number of subjects: 5661
Study 38418004 — intervention group
Group type: COMPARATOR
Intervention: sacubitril/valsartan vs ramipril
Number of subjects: 5661
Study 38418209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age 34-35 weeks
Number of subjects: 794
Study 38418209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age 37-38 weeks
Number of subjects: 794
Study 38418209 — intervention group
Group type: COMPARATOR
Intervention: Gestational age 39-40 weeks
Number of subjects: 794
Study 38418234 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab in combination with chemotherapy (CT)
Number of subjects: 0
Study 38418234 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study 38418236 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet of Things (IoT) management model
Number of subjects: 682
Study 38418244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health comorbidity in patients with IBD
Number of subjects: 1943
Study 38418244 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health comorbidity in patients with IBD aged ≥18 years
Number of subjects: 1943
Study 38418306 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital major adverse events (MAE)
Number of subjects: 1499
Study 38418306 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ICCU hospitalization
Number of subjects: 1499
Study 38418306 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced ICCU therapies
Number of subjects: 1499
Study 38418306 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive procedures
Number of subjects: 1499
Study 38418306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac imaging
Number of subjects: 1499
Study 38418343 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin (EV)
Number of subjects: 608
Study 38418350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet score (MDS)
Number of subjects: 765
Study 38418350 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH) score
Number of subjects: 765
Study 38418350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall plant-based diet index (PDI)
Number of subjects: 765
Study 38418350 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet index (hPDI)
Number of subjects: 765
Study 38418350 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet indices (PDIs)
Number of subjects: 765
Study 38418384 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with remote digital monitoring of home spirometry and pulse oximetry
Number of subjects: 132
Study 38418384 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 132
Study 38418563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cipaglucosidase alfa + miglustat (cipa + mig)
Number of subjects: 118
Study 38418563 — intervention group
Group type: COMPARATOR
Intervention: Alglucosidase alfa + placebo (alg + pbo)
Number of subjects: 118
Study 38418863 — intervention group
Group type: EXPERIMENTAL
Intervention: bioactive ionic resin composite (Activa Bioactive Base/Liner)
Number of subjects: 20
Study 38418863 — intervention group
Group type: EXPERIMENTAL
Intervention: resin-modified glass ionomer liner (Riva Light Cure)
Number of subjects: 20
Study 38418879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab (anti-TIGIT antibody) combined with atezolizumab (anti-PD-L1)
Number of subjects: 0
Study 38418879 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab (anti-PD-L1) alone
Number of subjects: 0
Study 38418982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA) paediatric granules, administered once daily for 3 days
Number of subjects: 667
Study 38418982 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL), comparator in two trials
Number of subjects: 667
Study 38418982 — intervention group
Group type: EXPERIMENTAL
Intervention: CANTAM study with PA
Number of subjects: 667
Study 38419024 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise therapy and education (ExE) and 10-module internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 15
Study 38419024 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA followed by ExE and iCBT
Number of subjects: 15
Study 38419024 — intervention group
Group type: COMPARATOR
Intervention: TKA and standard postoperative care
Number of subjects: 15
Study 38419024 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment and retention
Number of subjects: 15
Study 38419024 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 15
Study 38419024 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance to iCBT
Number of subjects: 15
Study 38419030 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactically guided intracerebral injection of CTX0E03, a fetal derived neural stem cell line.
Number of subjects: 86
Study 38419030 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid recruitment approach using a patient-facing web portal for initial screening and subsequent phone and medical record review.
Number of subjects: 86
Study 38419032 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive Cryotherapy (CC)
Number of subjects: 40
Study 38419032 — intervention group
Group type: COMPARATOR
Intervention: Standard Cryotherapy (SC)
Number of subjects: 40
Study 38419035 — intervention group
Group type: EXPERIMENTAL
Intervention: eclitasertib 600 mg (300 mg twice daily)
Number of subjects: 68
Study 38419035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 38419049 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0
Study 38419049 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency care
Number of subjects: 0
Study 38419058 — intervention group
Group type: EXPERIMENTAL
Intervention: OMIE approach along with dissemination of OEND best practice recommendations
Number of subjects: 105
Study 38419058 — intervention group
Group type: COMPARATOR
Intervention: Dissemination of OEND best practice recommendations (Control SSPs)
Number of subjects: 105
Study 38419068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie chronotype-adapted diet
Number of subjects: 150
Study 38419068 — intervention group
Group type: COMPARATOR
Intervention: Standardized low-calorie healthy eating plan
Number of subjects: 150
Study 38419075 — intervention group
Group type: EXPERIMENTAL
Intervention: VEERALIN® LN (PBO-py)
Number of subjects: 50
Study 38419075 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor® G2 LN (chlorfenapyr-py)
Number of subjects: 50
Study 38419075 — intervention group
Group type: COMPARATOR
Intervention: MAGNet® LN (control, py)
Number of subjects: 50
Study 38419119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 333
Study 38419119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 38419119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 333
Study 38419131 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-based PCR viral testing
Number of subjects: 72
Study 38419131 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care antigen testing
Number of subjects: 72
Study 38419131 — intervention group
Group type: COMPARATOR
Intervention: Both testing protocols (LAB and POC)
Number of subjects: 72
Study 38419131 — intervention group
Group type: COMPARATOR
Intervention: Concern for contracting COVID-19
Number of subjects: 72
Study 38419156 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-associated invasive fungal infections (CAIFIs)
Number of subjects: 276
Study 38419156 — intervention group
Group type: COMPARATOR
Intervention: No CAIFIs
Number of subjects: 276
Study 38419156 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIFIs
Number of subjects: 276
Study 38419159 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38419215 — intervention group
Group type: EXPERIMENTAL
Intervention: Saddle-contoured metal matrix (Group A)
Number of subjects: 60
Study 38419215 — intervention group
Group type: COMPARATOR
Intervention: Pre-contoured self-adhesive matrix (Group B)
Number of subjects: 60
Study 38419216 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional release technique (Group A)
Number of subjects: 64
Study 38419216 — intervention group
Group type: COMPARATOR
Intervention: Myofascial release technique (Group B)
Number of subjects: 64
Study 38419600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 13
Study 38419648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (two dosages)
Number of subjects: 75
Study 38419648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 38419711 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 71
Study 38419711 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 71
Study 38419787 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg and 25 mg pooled doses)
Number of subjects: 6967
Study 38419787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6967
Study 38419834 — intervention group
Group type: EXPERIMENTAL
Intervention: Total salt consumption (TS)
Number of subjects: 0
Study 38419834 — intervention group
Group type: EXPERIMENTAL
Intervention: Discretionary salt (DS) consumption
Number of subjects: 0
Study 38419834 — intervention group
Group type: COMPARATOR
Intervention: Bouillon contribution to total salt consumption
Number of subjects: 0
Study 38419905 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-assisted cognitive behavioral therapy (VR-CBT)
Number of subjects: 10
Study 38419905 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive behavioral therapy (CBT)
Number of subjects: 10
Study 38419981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low suction
Number of subjects: 50
Study 38419981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral suction (IOS)
Number of subjects: 50
Study 38419981 — intervention group
Group type: EXPERIMENTAL
Intervention: High & low suction
Number of subjects: 50
Study 38419981 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-oral suction (EOS) & low suction
Number of subjects: 50
Study 38419981 — intervention group
Group type: EXPERIMENTAL
Intervention: IOS & EOS
Number of subjects: 50
Study 38419981 — intervention group
Group type: COMPARATOR
Intervention: Control group (low or intraoral suction only)
Number of subjects: 50
Study 38419981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of suction devices (extra-oral with intra-oral suction, or extra-oral suction with low suction, or high & low suction)
Number of subjects: 50
Study 38419981 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate matter
Number of subjects: 50
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinking
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Current obesity
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular diseases
Number of subjects: 4800
Study 38420037 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 4800
Study 38420117 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise programme
Number of subjects: 60
Study 38420117 — intervention group
Group type: COMPARATOR
Intervention: Paper-based instructions
Number of subjects: 60
Study 38420260 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated viremic participants
Number of subjects: 20
Study 38420260 — intervention group
Group type: COMPARATOR
Intervention: Participants virologically controlled on ART
Number of subjects: 20
Study 38420356 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) injection with evidence-based treatment rationale
Number of subjects: 0
Study 38420356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-time 'Booster' group with one single repetition of the OLP injection at a fixed time point
Number of subjects: 0
Study 38420356 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand 'Booster' group with one single repetition of the OLP injection on-demand
Number of subjects: 0
Study 38420356 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving just one OLP injection
Number of subjects: 0
Study 38420657 — intervention group
Group type: EXPERIMENTAL
Intervention: elranatamab (12 mg on day 1, 32 mg on day 4, 76 mg on day 8, each cycle = 28 days)
Number of subjects: 187
Study 38420657 — intervention group
Group type: EXPERIMENTAL
Intervention: elranatamab
Number of subjects: 187
Study 38420809 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-related cell adhesion molecules (CAMs) identified through multi-omics data analysis and bioinformatics.
Number of subjects: 0
Study 38420809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor tissue and para-cancerous tissue samples from HCC patients validated using RT-PCR.
Number of subjects: 0
Study 38420848 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-rate aerobic exercise (FE) paired with upper extremity repetitive task practice (RTP)
Number of subjects: 60
Study 38420848 — intervention group
Group type: COMPARATOR
Intervention: RTP only
Number of subjects: 60
Study 38420947 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote training (RT group)
Number of subjects: 23
Study 38420947 — intervention group
Group type: COMPARATOR
Intervention: Self-study (SS group)
Number of subjects: 23
Study 38421092 — intervention group
Group type: COMPARATOR
Intervention: Seated resting-state heart rate variability (HRV) parameters in the α-OH group
Number of subjects: 81
Study 38421092 — intervention group
Group type: COMPARATOR
Intervention: Seated resting-state HRV parameters in the α-NOH group
Number of subjects: 81
Study 38421092 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of HRV parameters with blood pressure changes
Number of subjects: 81
Study 38421092 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated resting-state qEEG parameters in the α-OH group
Number of subjects: 81
Study 38421092 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak frequency of theta waves in the Cz region
Number of subjects: 81
Study 38421092 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of beta2 waves in Fp2 and F4 regions
Number of subjects: 81
Study 38421092 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal electrical activity in alpha, theta, and beta1 waves
Number of subjects: 81
Study 38421211 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y reconstruction
Number of subjects: 1167